Cargando…

Crizanlizumab: A CRITICAL Drug During a CRITICAL Time?

[Figure: see text]

Detalles Bibliográficos
Autores principales:	Gue, Ying X., Pula, Giordano, Lip, Gregory Y.H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8733743/ https://www.ncbi.nlm.nih.gov/pubmed/35024499 http://dx.doi.org/10.1016/j.jacbts.2021.10.013

Ejemplares similares

Complete revascularization in elderly patients with myocardial infarction—a safe, effective, and necessary strategy?
por: Gue, Ying X., et al.
Publicado: (2023)

Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease
por: Kanter, Julie, et al.
Publicado: (2022)

Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial
por: Leucker, Thorsten M., et al.
Publicado: (2021)

Impact of Crizanlizumab on Acute Medical Care Utilization in the Height of the COVID-19 Pandemic
por: Rao, Shivani, et al.
Publicado: (2021)

Hypertension and atrial fibrillation: Closing a virtuous circle
por: Gue, Ying X., et al.
Publicado: (2021)

Successful Treatment of SCD-Related Priapism With Crizanlizumab: A Case Series
por: Idowu, Modupe, et al.
Publicado: (2023)

Critical aortic stenosis presenting as STEMI
por: Gue, Ying X, et al.
Publicado: (2017)

UK media reporting of NICE recommendation of crizanlizumab for patients with sickle cell disease
por: Buka, Richard J, et al.
Publicado: (2022)

Real-World Data of Crizanlizumab in Sickle Cell Disease: A Single-Center Analysis
por: Cheplowitz, Halle, et al.
Publicado: (2023)

Stroke and bleeding risk stratification in atrial fibrillation: a critical appraisal
por: Lane, Deirdre A, et al.
Publicado: (2020)

Coffee and cardiac arrhythmias: Up-date review of the literature and clinical studies
por: Surma, Stanisław, et al.
Publicado: (2023)

Crizanlizumab and comparators for adults with sickle cell disease: a systematic review and network meta-analysis
por: Thom, Howard, et al.
Publicado: (2020)

Recent Advances in Sickle-Cell Disease Therapies: A Review of Voxelotor, Crizanlizumab, and L-glutamine
por: Migotsky, Michael, et al.
Publicado: (2022)

5610357 REDUCTION IN BLOOD TRANSFUSION BURDEN FOLLOWING INITIATION OF VOXELOTOR OR CRIZANLIZUMAB: A CASE SERIES
por: Baruwa Etti, A., et al.
Publicado: (2023)

The 2020 ESC Guidelines on the Diagnosis and Management of Atrial Fibrillation
por: Kotalczyk, Agnieszka, et al.
Publicado: (2021)

Photoplethysmography rhythm interpretation: an essential skill in an era of novel technologies
por: Gue, Ying X, et al.
Publicado: (2021)

Apixaban enhances endogenous fibrinolysis in patients with atrial fibrillation
por: Spinthakis, Nikolaos, et al.
Publicado: (2019)

Profile of crizanlizumab and its potential in the prevention of pain crises in sickle cell disease: evidence to date
por: Riley, Tanya R, et al.
Publicado: (2019)

Chronic Kidney Disease, Time in Therapeutic Range and Adverse Clinical Outcomes in Anticoagulated Patients with Non-valvular Atrial Fibrillation: Observations from the SPORTIF Trials
por: Proietti, Marco, et al.
Publicado: (2016)

An international survey of physician and patient understanding, perception, and attitudes to atrial fibrillation and its contribution to cardiovascular disease morbidity and mortality
por: Aliot, Etienne, et al.
Publicado: (2010)

P-Selectin Blockade in the Treatment of Painful Vaso-Occlusive Crises in Sickle Cell Disease: A Spotlight on Crizanlizumab
por: Karki, Nabin Raj, et al.
Publicado: (2021)

5613436 EXPERT CONSENSUS ON THE MANAGEMENT OF INFUSION-RELATED REACTIONS (IRRS) PRESENTING WITH PAIN IN PATIENTS RECEIVING CRIZANLIZUMAB
por: Kanter, J., et al.
Publicado: (2023)

PB2512: SAFETY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE: INTEGRATED POST-MARKETING SURVEILLANCE ANALYSIS
por: Abboud, Miguel, et al.
Publicado: (2023)

New use for an old drug: Metformin and atrial fibrillation
por: Vinciguerra, Manlio, et al.
Publicado: (2022)

Control of Anticoagulation Therapy in Patients with Atrial Fibrillation Treated with Warfarin: A Study from the Chinese Atrial Fibrillation Registry
por: Liang, Hai-Feng, et al.
Publicado: (2019)

Breast cancer and incident cardiovascular events: A systematic analysis at the nationwide level
por: Gue, Ying X., et al.
Publicado: (2022)

Season of Birth and Cardiovascular Mortality in Atrial Fibrillation: A Population-Based Cohort Study
por: Gue, Ying X., et al.
Publicado: (2021)

Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists
por: Lip, Gregory Y.H., et al.
Publicado: (2009)

Disparities in atrial fibrillation: a call for holistic care
por: Kotalczyk, Agnieszka, et al.
Publicado: (2021)

Atrial fibrillation, a contemporary sign of multimorbidity and irregular social inequity
por: Sagris, Dimitrios, et al.
Publicado: (2022)

Restoring the biological activity of crizanlizumab at physiological conditions through a pH-dependent aspartic acid isomerization reaction
por: Bickel, Fabian, et al.
Publicado: (2022)

The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell Disease
por: Delgado, Julio, et al.
Publicado: (2021)

Consumer-Led Screening for Atrial Fibrillation: A Report From the mAFA-II Trial Long-Term Extension Cohort
por: Guo, Yutao, et al.
Publicado: (2022)

Stroke Prevention in Atrial Fibrillation: Where are We Now?
por: Ahmad, Yousif, et al.
Publicado: (2012)

Endothelial Progenitors and Blood Microparticles: Are They Relevant to Heart Failure With Preserved Ejection Fraction?
por: Shantsila, Eduard, et al.
Publicado: (2016)

Editorial commentary: COVID-19 and COVID-19 vaccination: Observations on thrombosis and thrombocytopenia
por: Elsheikh, Sandra, et al.
Publicado: (2022)

P1441: REAL-WORLD OUTCOMES AND DIGITALLY MONITORED QUALITY OF LIFE IN CRIZANLIZUMAB-TREATED PATIENTS WITH SICKLE CELL DISEASE.
por: Summers, Kim, et al.
Publicado: (2023)

Timing of Tracheotomy in Mechanically Ventilated Critically Ill Morbidly Obese Patients
por: Alhajhusain, Ahmad, et al.
Publicado: (2014)

Impact of anti-arrhythmic drugs and catheter ablation on the survival of patients with atrial fibrillation: a population study based on 199 433 new-onset atrial fibrillation patients in the UK
por: Chung, Sheng-Chia, et al.
Publicado: (2022)

Developing a Communication System During the COVID Crisis for the Relatives of Critically Ill Patients
por: Lindsay, H, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_u80jc3a83u2a5uqk1fru4f5r26